Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 6Metastatic Castration-resistant Prostate Cancer 2PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Clear-cell metastatic renal cell carcinoma 1Astrocytoma 1

Interventions

Temozolomide 18Radiation 7Magnetic Resonance Spectroscopy 7Radiotherapy 6Specimen Handling 4Lomustine 4Bevacizumab 4Aminolevulinic Acid 3veliparib 2trametinib 2lutetium Lu 177 dotatate 2dabrafenib 2azeliragon 2Surgical Procedures, Operative 2Receptors, Interleukin-8B 2Nivolumab 2D2C7-(scdsFv)-PE38KDEL 2Carboplatin 2Biopsy 2varlilumab 1ulixertinib 1tinostamustine 1selinexor 1ruxolitinib 1ribociclib 1relatlimab 1regorafenib 1peposertib 1pembrolizumab 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × Pluvicto × 30 days × Clear all
NCT07223034 2026-06-04

A Study of 177Lu-PSMA-617 in People With Gliomas

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
20 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡